The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) for patients with newly ...

BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

In a significant shift for the treatment landscape of essential thrombocythemia (ET), the US National Comprehensive Cancer Network (NCCN) has designated ropeginterferon alfa-2b-njft (Besremi) as a ...

The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...

Ancestry-specific biomarkers, such as POLB, could reshape diagnostic and prognostic approaches in head and neck cancer. New ...

A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...

Dr. Shune continues the case discussion by describing disease progression following second-line therapy and outlining her approach to third-line treatment selection in cGVHD. After initiating systemic ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, discusses the safety and toxicity management of amivantamab ...